Publications by authors named "D G Generali"
Article Synopsis
- Antibody-drug conjugates (ADCs) T-DXd and SG improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in metastatic breast cancer (MBC) but have not been directly compared.
- A network meta-analysis revealed that T-DXd and SG had similar efficacy in hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low MBC, while T-DXd showed better results against standard chemotherapy.
- T-DXd demonstrated more favorable outcomes in HR+/HER2-low for both PFS and OS, but SG showed higher rates of specific side effects, including neutropenia and diarrhea, while T-DXd was associated with more serious adverse events like pneumonitis and cardiotoxicity
Purpose: we tested whether ctDNA changes may be used to assess early response and clinical outcome in metastatic colorectal cancer (mCRC) patients undergoing front-line systemic anti-cancer therapy (SACT).
Experimental Design: 862 plasma samples were collected 4-weekly from baseline (BL) until disease progression in mCRC patients receiving front line SACT. ctDNA normalization was defined as ≥99% clearance after 1 month of therapy (Mo1) in the 3 variants with the highest allele frequency in BL ctDNA.
Background: Glioblastoma is a highly aggressive primary central nervous system tumor characterized by poor outcomes. In case of relapse or progression to adjuvant chemotherapy, there is no univocal preferred regimen for relapsing glioblastoma.
Methods: We conducted a systematic review and Bayesian trial-level network meta-analyses (NMA) to identify the regimens associated with the best outcomes.
Purpose: The aim of this study was to assess the prognostic performance of the 70-gene signature, MammaPrint, in an Italian single-center prospective cohort of early-stage intermediate-risk breast cancer (BC) patients.
Methods: A total of 195 eligible early BC cases were tested for genomic risk between 2006 and 2013. In this retrospective analysis, the association of genomic risk with distant metastasis-free survival (DMFS) and overall survival (OS) were assessed using Cox regression models, adjusting for clinical and pathological tumor characteristics.